CAMBRIDGE, MA, FogPharma, a biopharmaceutical company, announced the company has raised a $107 million Series C financing led by venBio Partners.
FogPharma, a biopharmaceutical company pioneering a new class of precision medicines potentially applicable to all therapeutic targets, including those previously considered "undruggable", announced the company landed a $107 million Series C financing.
The financing was led by venBio Partners, with participation from new investors Cormorant Asset Management, Farallon Capital Management, Invus, funds and accounts advised by T. Rowe Price Associates, Inc.; HBM Healthcare Investments, Casdin Capital, and PagsGroup. Existing investors, including GV, 6 Dimensions Capital, Deerfield Management and Blue Pool Capital also participated in the oversubscribed round.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about